Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo
Entera Bio Ltd. · Hypoparathyroidism · Osteoporosis
Phase 1
Completed
45
2026-02
Industry sponsor intelligence
Entera Bio Ltd.Clinical Pipeline.
Lead-sponsor view of Entera Bio Ltd.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 2
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 0
- Avg enrollment
- 103
Pipeline overview
Programs by phase and activity.
Velocity
Entera Bio Ltd. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 11
Phase 21
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Teriparatide → | 2 | 1 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
Entera Bio Ltd. · Osteoporosis
Phase 2
Completed
161
2021-06
Search sponsor records
All Entera Bio Ltd. studies.
This page groups studies where Entera Bio Ltd. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
2 matching studies
Last registry update first